Hydrocortisone/lidocaine - Citius Pharmaceuticals

Drug Profile

Hydrocortisone/lidocaine - Citius Pharmaceuticals

Alternative Names: CITI-001; CITI-002; Hydro-Lido; Hydrocortisone acetate/lidocaine hydrochloride - Citius Pharmaceuticals

Latest Information Update: 09 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Citius Pharmaceuticals LLC
  • Developer Citius Pharmaceuticals Inc
  • Class Acetanilides; Anti-inflammatories; Antiallergics; Class Ib antiarrhythmics; Glucocorticoids; Local anaesthetics; Pregnenediones
  • Mechanism of Action Glucocorticoid receptor agonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Haemorrhoids

Most Recent Events

  • 06 Mar 2018 Citius Pharmaceuticals conducts Type C meeting with US FDA regarding planned phase IIb study of CITI-002 formulation of hydrocortisone/lidocaine for treatment of Haemorrhoids
  • 06 Mar 2018 Citius Pharmaceuticals plans a phase IIb and a phase III trial of CITI-002 for Haemorrhoids
  • 04 Nov 2015 Phase-IIa clinical trials in Haemorrhoids in USA (Topical) before November 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top